FY2029 Earnings Estimate for MLTX Issued By Leerink Partnrs

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will earn $8.17 per share for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

A number of other research firms have also commented on MLTX. The Goldman Sachs Group raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $62.00 to $82.00 in a research report on Friday, January 17th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Friday, January 10th. Finally, Wedbush reissued an “outperform” rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $84.29.

MoonLake Immunotherapeutics Stock Up 1.0 %

Shares of NASDAQ:MLTX opened at $47.11 on Friday. The company has a 50-day moving average price of $50.02 and a 200-day moving average price of $49.04. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same quarter last year, the firm earned ($0.18) EPS.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE purchased a new position in MoonLake Immunotherapeutics during the 3rd quarter valued at about $44,000. Barclays PLC increased its stake in shares of MoonLake Immunotherapeutics by 1,269.2% during the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after purchasing an additional 5,229 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of MoonLake Immunotherapeutics by 26.2% during the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after purchasing an additional 2,700 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter worth approximately $706,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter worth approximately $741,000. 93.85% of the stock is owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.